CU20120006A7 - Producción de títulos elevados de poliovirus para la producción de vacunas - Google Patents

Producción de títulos elevados de poliovirus para la producción de vacunas

Info

Publication number
CU20120006A7
CU20120006A7 CU2012000006A CU20120006A CU20120006A7 CU 20120006 A7 CU20120006 A7 CU 20120006A7 CU 2012000006 A CU2012000006 A CU 2012000006A CU 20120006 A CU20120006 A CU 20120006A CU 20120006 A7 CU20120006 A7 CU 20120006A7
Authority
CU
Cuba
Prior art keywords
production
poliovirus
cells
titles
vaccines
Prior art date
Application number
CU2012000006A
Other languages
English (en)
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CU20120006A7 publication Critical patent/CU20120006A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Proceso para la producción de poliovirus que comprende los siguientes pasos: a) proveer un cultivo de células en una suspensión libre de suero, donde dichas células son células PER.C6, b) infectar dichas células con poliovirus en una densidad celular de entre 2x10 elevado a 6 células/ml y 150x10 elevado a 6 células/ml, y c) cosechar los poliovirus entre 12 y 48 horas después de la infección.
CU2012000006A 2009-07-16 2012-01-13 Producción de títulos elevados de poliovirus para la producción de vacunas CU20120006A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09165620 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Publications (1)

Publication Number Publication Date
CU20120006A7 true CU20120006A7 (es) 2012-10-15

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000006A CU20120006A7 (es) 2009-07-16 2012-01-13 Producción de títulos elevados de poliovirus para la producción de vacunas

Country Status (32)

Country Link
US (4) US8546123B2 (es)
EP (1) EP2454364B1 (es)
JP (1) JP5845178B2 (es)
KR (1) KR101548790B1 (es)
CN (1) CN102482647B (es)
AP (1) AP3140A (es)
AR (1) AR077314A1 (es)
AU (1) AU2010272685B2 (es)
BR (1) BR112012000942B8 (es)
CA (1) CA2763091C (es)
CO (1) CO6491042A2 (es)
CU (1) CU20120006A7 (es)
DK (1) DK2454364T3 (es)
EA (1) EA020563B1 (es)
ES (1) ES2484093T3 (es)
HR (1) HRP20140597T1 (es)
IL (1) IL217465A (es)
MA (1) MA33429B1 (es)
MX (1) MX2011012648A (es)
MY (1) MY183385A (es)
NZ (1) NZ596880A (es)
PE (1) PE20120571A1 (es)
PL (1) PL2454364T3 (es)
PT (1) PT2454364E (es)
RS (1) RS53377B (es)
SG (1) SG177655A1 (es)
SI (1) SI2454364T1 (es)
SM (1) SMT201400079B (es)
TN (1) TN2011000628A1 (es)
TW (1) TWI477606B (es)
WO (1) WO2011006823A1 (es)
ZA (1) ZA201108271B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
BR112015021523A8 (pt) 2013-03-08 2021-06-29 Crucell Holland Bv composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
WO2014142433A1 (ko) 2013-03-13 2014-09-18 고려대학교산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
RS57864B1 (sr) 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
JP6591461B2 (ja) 2014-06-17 2019-10-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 低温適応性ウイルス弱毒化（ｃａｖａ）および新規の弱毒化ポリオウイルス株
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
DK3172317T3 (da) * 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
EP3749757A4 (en) * 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP3969046A1 (en) 2019-05-16 2022-03-23 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
RS20070078A (sr) 2004-08-27 2008-11-28 Panacea Biotec Ltd., Inaktivirana vakcina protiv poliomijelitisa nastala iz sabinovog soja polio virusa
BRPI0518146A (pt) * 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
WO2008059041A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
TWI477606B (zh) 2015-03-21
NZ596880A (en) 2013-10-25
PL2454364T3 (pl) 2014-09-30
JP5845178B2 (ja) 2016-01-20
CN102482647A (zh) 2012-05-30
US20110027317A1 (en) 2011-02-03
KR20120033334A (ko) 2012-04-06
EP2454364B1 (en) 2014-04-23
AP3140A (en) 2015-02-28
US9022240B2 (en) 2015-05-05
BR112012000942A2 (pt) 2016-03-15
IL217465A0 (en) 2012-02-29
US20130273106A1 (en) 2013-10-17
BR112012000942B8 (pt) 2021-05-25
SG177655A1 (en) 2012-02-28
WO2011006823A1 (en) 2011-01-20
HRP20140597T1 (hr) 2014-09-12
DK2454364T3 (da) 2014-07-21
AU2010272685A1 (en) 2011-12-08
MX2011012648A (es) 2012-01-12
PE20120571A1 (es) 2012-06-06
SI2454364T1 (sl) 2014-08-29
US8546123B2 (en) 2013-10-01
AR077314A1 (es) 2011-08-17
HK1164922A1 (en) 2012-09-28
RS53377B (sr) 2014-10-31
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
AP2012006075A0 (en) 2012-02-29
CN102482647B (zh) 2015-12-16
MY183385A (en) 2021-02-18
US20130052224A1 (en) 2013-02-28
US20140242670A1 (en) 2014-08-28
BR112012000942B1 (pt) 2020-10-27
MA33429B1 (fr) 2012-07-03
SMT201400079B (it) 2014-09-08
JP2012532616A (ja) 2012-12-20
IL217465A (en) 2016-05-31
ES2484093T3 (es) 2014-08-11
CA2763091C (en) 2019-07-23
EP2454364A1 (en) 2012-05-23
KR101548790B1 (ko) 2015-08-31
TN2011000628A1 (en) 2013-05-24
EA201270173A1 (ru) 2012-06-29
TW201118173A (en) 2011-06-01
PT2454364E (pt) 2014-07-04
EA020563B1 (ru) 2014-12-30
ZA201108271B (en) 2012-07-25
CA2763091A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CO6491042A2 (es) Produccion de titulos elevados de poliovirus para la produccion de vacunas
AR132548A2 (es) Medio de cultivo para células cho libre de suero que comprende ornitina y putrescina, método para cultivar células cho y método in vitro para producir una proteína
AR111785A2 (es) Método in vitro de producción de eritrocitos
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
CO6612206A2 (es) Cultivo de árbol taray para combustible de biomasa
WO2009034927A1 (ja) 細胞培養器具及びこれを用いた細胞培養方法
AR076225A1 (es) Administracion de nanoparticulas revestidas de una secuencia de nucleasa especifica
AR058140A1 (es) Metodo de produccion proteica utilizando compuestos anti-senescencia
WO2011133902A3 (en) Cell culture medium comprising small peptides
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
MX2019015525A (es) Modificacion genetica de ratas.
MX2012007634A (es) Filtro para un articulo para fumar.
SG178914A1 (en) Stem cell conditioned medium compositions
EP2588594A4 (en) PROCESS FOR CULTIVATING UNDIFFERENCED CELLS USING DELAYED RELATED COMPOSITION COMPOSITIONS
BR0313559A (pt) Método para o cultivo de células primárias e para a amplificação de vìrus sob condições isentas de soro
MX343113B (es) Medios de cultivo de celulas granulados en seco.
MX387420B (es) Producción de virus en cultivos celulares.
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
AR082374A1 (es) Proceso de fermentacion para streptococcus pneumoniae
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa
CL2013002723A1 (es) Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto.
ES2351296B8 (es) Cepas de s. cerevisiae capaces de crecer en medios con melibiosa, estaquiosa y rafinosa.
AR124307A1 (es) Métodos de producción de adenovirus
AR076144A1 (es) Metodo de obtencion y produccion masiva de una especie de cianobacteria aislada productora de ficotoxinas paralizantes